Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$13.54 - $22.74 $760,948 - $1.28 Million
-56,200 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$12.91 - $23.83 $725,542 - $1.34 Million
56,200 New
56,200 $1.07 Million

Others Institutions Holding HGEN

About HUMANIGEN, INC


  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Css LLC Portfolio

Follow Css LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.